224 related articles for article (PubMed ID: 37445743)
1. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results.
Okonogi N; Murata K; Yamada S; Habu Y; Hori M; Kurokawa T; Inaba Y; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Koto M; Hasegawa S; Ishikawa H; Hanaoka H; Shozu M; Tsuji H; Usui H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445743
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N; Usui H; Murata K; Hori M; Kurokawa T; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Hasegawa S; Yamada S; Hanaoka H; Shozu M; Tsuji H
BMJ Open; 2022 Mar; 12(3):e056424. PubMed ID: 35236732
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
[TBL] [Abstract][Full Text] [Related]
4. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001).
Okonogi N; Wakatsuki M; Kato S; Karasawa K; Kiyohara H; Shiba S; Kobayashi D; Nakano T; Kamada T; Shozu M;
Cancer Med; 2018 Feb; 7(2):351-359. PubMed ID: 29341491
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1/2 Study of Carbon Ion Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Uterine Cervical Squamous Cell Carcinoma (Protocol 1302).
Okonogi N; Wakatsuki M; Kato S; Karasawa K; Miyasaka Y; Murata H; Nakano T; Kamada T; Shozu M;
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):631-639. PubMed ID: 30825494
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
10. Significance of concurrent use of weekly cisplatin in carbon-ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score-matched analysis.
Okonogi N; Wakatsuki M; Kato S; Murata H; Kiyohara H; Karasawa K; Ohno T; Tsuji H; Nakano T; Shozu M;
Cancer Med; 2020 Feb; 9(4):1400-1408. PubMed ID: 31891228
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
Umayahara K; Takekuma M; Hirashima Y; Noda SE; Ohno T; Miyagi E; Hirahara F; Hirata E; Kondo E; Tabata T; Nagai Y; Aoki Y; Wakatsuki M; Takeuchi M; Toita T; Takeshima N; Takizawa K
Gynecol Oncol; 2016 Feb; 140(2):253-8. PubMed ID: 26701414
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres.
Hoskin P; Lee M; Dunkley D; Danh M; Wickens R; Saunders G; Northey J; Crabb S; McFarlane V; Sadozye A; Cooper R; Mathew T; Haslett K; Reeves K; Reed R; Bigos K; Williams KJ; Rowling E; Choudhury A; Dancer S; Smith D; Griffiths G
BMC Cancer; 2024 Jun; 24(1):702. PubMed ID: 38849715
[TBL] [Abstract][Full Text] [Related]
13. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial.
Umanzor J; Aguiluz M; Pineda C; Andrade S; Erazo M; Flores C; Santillana S
Gynecol Oncol; 2006 Jan; 100(1):70-5. PubMed ID: 16288803
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer.
Li J; Li Y; Wang H; Shen L; Wang Q; Shao S; Shen Y; Xu H; Liu H; Cai R; Feng W
BMC Cancer; 2023 Jan; 23(1):51. PubMed ID: 36641433
[TBL] [Abstract][Full Text] [Related]
17. 'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Rotman J; Mom CH; Jordanova ES; de Gruijl TD; Kenter GG
BMC Cancer; 2018 Sep; 18(1):888. PubMed ID: 30208866
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V
J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
